ChromaDex (CDXC) Stock Price, News & Analysis

Company Overview

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Key Stats

• Today's Range: $5.25 to $5.55
• 50-Day Range: $3.35 to $7.72
• 52-Week Range: $1.36 to $7.97
• Volume: 1.20 million shs
• Average Volume: 555,431 shs
• Market Capitalization: $419.34 million
• P/E Ratio: 549.55
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

ChromaDex Stock Analysis - MarketRank™

ChromaDex scored higher than 92% of companies evaluated by MarketBeat, and ranked 83rd out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ChromaDex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ChromaDex has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 200.00%

Earnings Growth

Earnings for ChromaDex are expected to grow by 200.00% in the coming year, from $0.04 to $0.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ChromaDex is 549.55, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 115.29.

Price to Earnings Ratio vs. Sector

The P/E ratio of ChromaDex is 549.55, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 91.08.

Price to Book Value per Share Ratio

ChromaDex has a P/B Ratio of 14.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.15% of the float of ChromaDex has been sold short.

Short Interest Ratio / Days to Cover

ChromaDex has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ChromaDex has recently decreased by 6.10%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ChromaDex does not currently pay a dividend.

Dividend Growth

ChromaDex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.85

Percentage of Shares Shorted

4.15% of the float of ChromaDex has been sold short.

Short Interest Ratio / Days to Cover

ChromaDex has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ChromaDex has recently decreased by 6.10%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: N/A

News Sentiment

ChromaDex has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ChromaDex this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for CDXC on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added ChromaDex to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ChromaDex insiders have sold 975.09% more of their company's stock than they have bought. Specifically, they have bought $21,396.00 in company stock and sold $230,027.00 in company stock.

Percentage Held by Insiders

Only 9.64% of the stock of ChromaDex is held by insiders.

Percentage Held by Institutions

Only 15.41% of the stock of ChromaDex is held by institutions.

CDXC Stock Analysis - Frequently Asked Questions

How have CDXC shares performed this year?

ChromaDex's stock was trading at $1.43 at the beginning of the year. Since then, CDXC stock has increased by 283.9% and is now trading at $5.49.
View the best growth stocks for 2024 here.

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) released its quarterly earnings results on Thursday, October, 31st. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.02. The company earned $25.58 million during the quarter, compared to analysts' expectations of $23.70 million. ChromaDex had a net margin of 1.62% and a trailing twelve-month return on equity of 4.85%.

Who are ChromaDex's major shareholders?

ChromaDex's top institutional shareholders include Tieton Capital Management LLC (3.87%), Geode Capital Management LLC (1.51%), State Street Corp (0.81%) and Connor Clark & Lunn Investment Management Ltd. (0.23%). Insiders that own company stock include Hoi Shuen Solina Holly Chau, Frank L Jaksch Jr, Robert N Fried, Brianna Gerber, Steven D Rubin and Kristin Patrick.
View institutional ownership trends.

How do I buy shares of ChromaDex?

Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ChromaDex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ChromaDex investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 10/31/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CDXC
• CUSIP: N/A
• CIK: 1386570
• Web: www.chromadex.com
• Phone: (310) 388-6706
• Fax: 949-419-0294
• Employees: 106
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +45.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.01
• Trailing P/E Ratio: 549.55
• Forward P/E Ratio: 137.25
• P/E Growth: N/A
• Net Income: $-4,940,000.00
• Net Margins: 1.62%
• Pretax Margin: 1.62%
• Return on Equity: 4.85%
• Return on Assets: 2.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.95
• Quick Ratio: 2.35

Sales & Book Value

• Annual Sales: $91.67 million
• Price / Sales: 4.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.38 per share
• Price / Book: 14.45

Miscellaneous

• Outstanding Shares: 76,383,000
• Free Float: 69,020,000
• Market Cap: $419.34 million
• Optionable: Optionable
• Beta: 2.16